Extranodal nasal-type NK/T cell lymphoma appeared as EBV-associated hemophagocytic syndrome:a case report and literature review
ZHAO Bingbing,WANG Li,SHEN Zhixiang,CHEN Qiusheng
DOI: https://doi.org/10.13201/j.issn.1004-2806.2013.03.008
2013-01-01
Abstract:Objective:To report a case of extranodal nasal NK/T cell lymphoma appeared as EB virus-associated hemophagocytic lymphoid histiocytosis(EBV-HLH),and to review the relative literatures.Method:The clinical features of a rare case of nasal NK/T cell lymphoma with EBV-HLH as first symptoms were collocted,including disease history,physical examination,blood and bone marrow cytology,PET-CT imaging and histopathological findings.Result:A 27-year-old female patient sufferd from fever,sore throat,cough and joint pain.Because of progressive pancytopenia,fever,hepatosplenomegaly,low fibrinogen,high triglyceride and EBV-positive test,the patient was diagnosed as EBV-HLH.Then the patient received immunosuppressive therapy and her clinical features were improved.One month later,the patient suffered from herpes zoster and progressive obstruction of nose.Inferior turbinate biopsy and pathological analysis showed that tumor cells expressed CD56+/-,TIA1+,GB+,PF+,CD3+,CD43+,L26-,PAX5-,CD21-,CD30-,KP1-,Ki-67+(60%)and EREB+.Thus the patient was diagnosed as nasal-type NK/T cell lymphoma and received VP16based chemotherapy plus radiotherapy.The patient finally died after 6months.Conclusion:This case demonstrates the process from EBV-HLH to nasal NK/T cell lymphoma.It implies that the EBV infection,HLH and NK/T lymphoma are related.It is reported that lymphoma with HLH has worse prognosis than lymphoma without HLH.It is rare that HLH appeares before lymphoma and prognosis is the worst in this situation.There are no standard therapies for NK/T cell lymphoma with HLH.In some case reports early use of VP16based regimens as well as allogeneic hematopoietic stem cell transplantation may be effective for high-risk patients.But it still need to be approved by further large scale clinical trials.